FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387256107> ?p ?o ?g. }

• W4387256107 endingPage "A3771" @default.
• W4387256107 startingPage "A3771" @default.
• W4387256107 abstract "SESSION TITLE: Education, Research, and Quality Improvement Posters 8 SESSION TYPE: Original Investigation Posters PRESENTED ON: 10/11/2023 12:00 pm - 12:45 pm PURPOSE: Lung cancer is the leading cause of cancer deaths in both men and women in the US. Screening with LDCT allows for early detection of lung cancer which usually started as lung nodule.The challenge is determining which nodule should be investigated with biopsy, and which can be followed with CT surveillance. The Solitary Pulmonary Nodule (SPN) Malignancy Risk Score by Mayo Clinic is a useful tool which calculates the probability of malignancy of lung nodules. In addition, there is a novel blood-based test called Nodify Lung which uses autoantibodies to stratify risk of malignancy. This study is to correlate the Mayo SPN score, Nodify Lung blood test score, and the biopsy results of the participants METHODS: This study is a retrospective record review that has been carried out for all patients with pulmonary nodules who underwent the Nodify Lung test (CDT and Xl2) from January 2019 to November 2022 at the specified research site. It is an observational, non-interventional study with 84 participants. Clinical records have been accessed by the team of authors. Statistical analysis will be done using IBM-SPSS Statistics, Version 27. RESULTS: Total of 84 subjects were included in the study. 50% (42) of those were males and 50% (42) were females with a mean age of 69 years. All participants underwent Nodify Lung blood test. The participants were scored as either low (< 5% risk), intermediate (5-65% risk), or high (>65% risk) on basis of the Mayo calculator. Out of the 84 participants, 3 (3.57%) participants scored as low risk, 77 (91.67%) scored as intermediate risk and 4 (4.76%) scored as high risk for the nodule to be malignant. After Nodify lung test, participants were categorized into 3 risk levels. 43 participants (51.19%) were now considered low risk (<5%) post-Nodify, 35 participants (41.67%) were intermediate risk (5-65%) and 6 participants (7.14%) were high risk (>65%) for malignancy. When comparing the pre- and post-risk assessment, the risk for malignancy was lowered in 40 participants (47.62%). In 41 participants (48.81%), the risk stayed the same from pre-assessment to post-assessment, and in three participants (3.57%), the risk was increased after the Nodify Lung blood test. Of the post-Nodify lowered risk category, 4 patients underwent biopsy at the recommendation of the physician due to high suspicion of malignant nodules. Out of these 4, two participants were diagnosed with cancer. Of the increased risk category, 2 patients refused biopsy and 1 patient underwent biopsy and was diagnosed as cancer positive. Of the category with unchanged indeterminate risk post-Nodify, 8 patients underwent biopsy, and all had a diagnosis of cancer. CONCLUSIONS: The Solitary Pulmonary Nodule (SPN) tool by Mayo Clinic is a valuable tool in assessing for malignancy. When used in conjunction with the Nodify blood test, risk of malignancy can be identified, and plans of care can be created based on results. CLINICAL IMPLICATIONS: By identifying risk with both the SPN tool by Mayo Clinic and the Nodify blood test, patients are sent for biopsy and have a diagnosis quickly. DISCLOSURES: No relevant relationships by Nosheen Joyo No relevant relationships by Urwa Joyo No relevant relationships by Emma Nicholas No relevant relationships by Madeeha Shahzadi No relevant relationships by Jiya Sharma" @default.
• W4387256107 created "2023-10-03" @default.
• W4387256107 creator A5014213165 @default.
• W4387256107 creator A5042312093 @default.
• W4387256107 creator A5043250613 @default.
• W4387256107 creator A5044743104 @default.
• W4387256107 creator A5092986054 @default.
• W4387256107 date "2023-10-01" @default.
• W4387256107 modified "2023-10-03" @default.
• W4387256107 title "CORRELATION OF A NOVEL BIOMARKER TEST WITH OLD RISK CALCULATOR FOR THE DETECTION OF LUNG CANCER" @default.
• W4387256107 doi "https://doi.org/10.1016/j.chest.2023.07.2452" @default.
• W4387256107 hasPublicationYear "2023" @default.
• W4387256107 type Work @default.
• W4387256107 citedByCount "0" @default.
• W4387256107 crossrefType "journal-article" @default.
• W4387256107 hasAuthorship W4387256107A5014213165 @default.
• W4387256107 hasAuthorship W4387256107A5042312093 @default.
• W4387256107 hasAuthorship W4387256107A5043250613 @default.
• W4387256107 hasAuthorship W4387256107A5044743104 @default.
• W4387256107 hasAuthorship W4387256107A5092986054 @default.
• W4387256107 hasBestOaLocation W43872561071 @default.
• W4387256107 hasConcept C121608353 @default.
• W4387256107 hasConcept C126322002 @default.
• W4387256107 hasConcept C126838900 @default.
• W4387256107 hasConcept C143998085 @default.
• W4387256107 hasConcept C151730666 @default.
• W4387256107 hasConcept C2775934546 @default.
• W4387256107 hasConcept C2776256026 @default.
• W4387256107 hasConcept C2776731575 @default.
• W4387256107 hasConcept C2777405583 @default.
• W4387256107 hasConcept C2777714996 @default.
• W4387256107 hasConcept C2779399171 @default.
• W4387256107 hasConcept C2779563453 @default.
• W4387256107 hasConcept C2779599708 @default.
• W4387256107 hasConcept C71924100 @default.
• W4387256107 hasConcept C86803240 @default.
• W4387256107 hasConceptScore W4387256107C121608353 @default.
• W4387256107 hasConceptScore W4387256107C126322002 @default.
• W4387256107 hasConceptScore W4387256107C126838900 @default.
• W4387256107 hasConceptScore W4387256107C143998085 @default.
• W4387256107 hasConceptScore W4387256107C151730666 @default.
• W4387256107 hasConceptScore W4387256107C2775934546 @default.
• W4387256107 hasConceptScore W4387256107C2776256026 @default.
• W4387256107 hasConceptScore W4387256107C2776731575 @default.
• W4387256107 hasConceptScore W4387256107C2777405583 @default.
• W4387256107 hasConceptScore W4387256107C2777714996 @default.
• W4387256107 hasConceptScore W4387256107C2779399171 @default.
• W4387256107 hasConceptScore W4387256107C2779563453 @default.
• W4387256107 hasConceptScore W4387256107C2779599708 @default.
• W4387256107 hasConceptScore W4387256107C71924100 @default.
• W4387256107 hasConceptScore W4387256107C86803240 @default.
• W4387256107 hasIssue "4" @default.
• W4387256107 hasLocation W43872561071 @default.
• W4387256107 hasOpenAccess W4387256107 @default.
• W4387256107 hasPrimaryLocation W43872561071 @default.
• W4387256107 hasRelatedWork W2003370711 @default.
• W4387256107 hasRelatedWork W2078573701 @default.
• W4387256107 hasRelatedWork W2091944169 @default.
• W4387256107 hasRelatedWork W2278533172 @default.
• W4387256107 hasRelatedWork W3205158931 @default.
• W4387256107 hasRelatedWork W4283160551 @default.
• W4387256107 hasRelatedWork W4317600173 @default.
• W4387256107 hasRelatedWork W4318302273 @default.
• W4387256107 hasRelatedWork W4386759863 @default.
• W4387256107 hasRelatedWork W4386787149 @default.
• W4387256107 hasVolume "164" @default.
• W4387256107 isParatext "false" @default.
• W4387256107 isRetracted "false" @default.
• W4387256107 workType "article" @default.